Press Releases :: Ligand Pharmaceuticals Incorporated (LGND)

Press Releases

Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes

September 13, 2016

Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis

September 7, 2016

Ligand to Participate in Two Upcoming Investor Conferences

September 2, 2016

Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism

August 15, 2016

Ligand Reports Second Quarter 2016 Financial Results

August 4, 2016

Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals

July 29, 2016

Ligand to Report Second Quarter Results on August 4th

July 14, 2016

Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences

July 8, 2016

Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements

June 30, 2016

Ligand Reports First Quarter 2016 Financial Results

May 4, 2016

Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million

May 4, 2016

Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences

April 22, 2016

Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP

April 7, 2016

Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics

March 28, 2016

Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection

March 15, 2016